No Data
No Data
Leerink Partners Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6
Compass Therapeutics Price Target Raised to $24.00/Share From $10.00 by HC Wainwright & Co.
Compass Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Raises Target Price to $11
Leerink Partners Upgrades Compass Therapeutics(CMPX.US) to Buy Rating, Raises Target Price to $6
101853057 : Thank you.
Eugh : you should switch roles with moomoo and shaker
Hutao888 : good boy now make a list of guaranteed winnings!!!
Jaguar8 OP Hutao888 : ???
Alex Zhang155 : Thank you for your help. What do you think of STSS.
View more comments...